SCHEMBL13748825

SCHEMBL13748825

CC(C)c1c(Cl)cc(N(C)C)cc1C#N

nearest known ligand 0.39

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
PGR P06401 6/20 0.34
KDM5A P29375 1/20 0.34
AR P10275 1/20 0.32
TRPV4 Q9HBA0 1/20 0.32
CYP2C19 P33261 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12986726 0.80 TSHR (0.36)
SCHEMBL13755145 0.78 ALDH1A1 (0.33) PGRARTRPV4
SCHEMBL807523 0.76 TRPV4 (0.34) KDM5AARTRPV4
SCHEMBL26457742 0.76 ALDH1A1 (0.35) KDM5AARTRPV4
SCHEMBL13748821 0.74 AR (0.36) ARTRPV4
SCHEMBL15274595 0.74 ALDH1A1 (0.38) ARTRPV4CYP2C19
SCHEMBL2677378 0.72 TRPV4 (0.52) PGRARTRPV4CYP2C19
SCHEMBL13748310 0.71 AR (0.36) PGRAR
SCHEMBL13748798 0.70 AR (0.44) ARTRPV4
SCHEMBL11960298 0.70 AR (0.31) ARTRPV4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835423-B2 Azepine inhibitors of janus kinases INCYTE CORPORATION (US) 2014-09-16 US disclosed
US-20140031344-A1 AZEPINE INHIBITORS OF JANUS KINASES INCYTE CORPORATION (US) 2014-01-30 US disclosed
US-8563541-B2 Azepine inhibitors of Janus kinases INCYTE CORPORATION (US) 2013-10-22 US disclosed
US-20120329782-A1 AZEPINE INHIBITORS OF JANUS KINASES INCYTE CORPORATION (US) 2012-12-27 US disclosed
US-20120329782-A1 AZEPINE INHIBITORS OF JANUS KINASES INCYTE CORPORATION (US) 2012-12-27 US disclosed
US-20090197869-A1 AZEPINE INHIBITORS OF JANUS KINASES INCYTE CORPORATION, A DELAWARE CORPORATION 2009-08-06 US disclosed
US-20070149506-A1 Azepine inhibitors of Janus kinases INCYTE CORPORATION 2007-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329782-A1 AZEPINE INHIBITORS OF JANUS KINASES JAK1, JAK3, JAK2 PGR 1294/4885KDM5A 177/4885AR 3101/4885
US-20090197869-A1 AZEPINE INHIBITORS OF JANUS KINASES JAK1, JAK3, JAK2 PGR 1294/4885KDM5A 177/4885AR 3101/4885
US-20070149506-A1 Azepine inhibitors of Janus kinases JAK1, JAK3, JAK2 PGR 1294/4885KDM5A 177/4885AR 3101/4885
US-20140031344-A1 AZEPINE INHIBITORS OF JANUS KINASES JAK1, JAK3, JAK2 PGR 1294/4885KDM5A 177/4885AR 3101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.